Background竊�There are very limited data regarding role of statins in managing acute ST-segment elevation myocardial infarction (STEMI), especially in drug-eluting stent (DES) era.Method: The study population consisted of 4304 consecutive STEMI patients (pts) enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR) study from November 2005 to April 2008. Ninety two % of the STEMI pts underwent percutaneous coronary intervention (PCI) with DES and rest of the pts received either BMS or thrombolysis. Statin types and doses were depending on the physician���s discretion and 3355 pts were received from the presentation time. We investigated the clinical outcomes using propensity score (PS) adjustment between 3355 statin-naïve patients and those without statin treatment (n=949) up to 12 months.Results: The baseline characteristics were similar between the two groups, except that pts in Statins group were younger than no statin group (61.2짹12.6 vs 63.2짹12.4, p<0.05). Mortality, repeat PCI predominantly derived by less non-TVR, recurrent AMI and total major adverse cardiac events (MACE) were significantly lower in the statin group (Table). Statin administration was associated with less incidence of MACE at 12 months (ORunadjusted:0.559, 95% CI: 0.453-0.691, P<0.01; ORadjusted by ps:0.654, 95% CI: 0.505-0.847, P=0.001).Conclusion: Routine administration of Statins in acute STEMI pts regardless of the revascularization strategy showed better 12-month clinical outcomes compared with those of STEMI pts without statin therapy.